Week in Review: The Pipeline to Patient Well-being

Week in Review: The Pipeline to Patient Well-being

07.25.14 | By

Biopharmaceutical research and development (R&D) continues to thrive. This week, we examined some of the ways that medicines in development have opened new doors for patients and what we can do to maintain a bright and promising future.

The new Medicines in Development report on Arthritis and other musculoskeletal diseases reinforced that the pipeline is well-positioned to continue to bring new treatments to patients. Approximately 52 million Americans are affected by the more than 100 different types of musculoskeletal diseases, which results in 44 million outpatient visits each year. Thankfully there are nearly 100 medicines in development aimed at helping those individuals suffering from severe pain and discomfort. For more, read the full report here.

As the pipeline continues to bring treatments to patients, the future of medicine remains promising, which was evident from our new Conversations forum question. We asked experts to weigh in on personalized medicine, which is transforming the way we diagnose and treat patients with diseases such as cancer. Unfortunately, the benefits of such treatments are not yet common knowledge. Watch videos of experts as they explain personalized medicines and how they can help patients live longer, healthier lives.

In addition to highlighting the bright and promising future for medicines, often, the biopharmaceutical industry must address various misconceptions. This week, we debunked common myths pertaining to hepatitis C giving the ongoing debate surrounding the cost and value of new medicines.

Learn more about hepatitis C and the progress we’re making to help treat patients suffering from this and other debilitating conditions by following us on Facebook and Twitter. We also encourage you to get involved during World Hepatitis Day on Monday, July 28, by using the hashtags #ThinkHepatitis and #WorldHepatitisDay. We look forward to hearing from you!


Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context